---
title: "Ascendis Pharma reports Week 104 ApproaCH trial data showing improved leg alignment with TransCon CNP in achondroplasia"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290873855.md"
description: "Ascendis Pharma will present Week 104 data from the pivotal ApproaCH trial at ICCBH 2026, showing continued improvements in lower-limb alignment for achondroplasia patients treated with TransCon CNP (Yuviwel). Additionally, a late-breaking poster will share 52-week results from the Phase 2 COACH study on TransCon CNP combined with TransCon hGH. The company highlights benefits across key complications like limb growth and spinal issues. Yuviwel is marketed in the US, with an EMA filing pending."
datetime: "2026-06-25T20:01:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290873855.md)
  - [en](https://longbridge.com/en/news/290873855.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290873855.md)
---

# Ascendis Pharma reports Week 104 ApproaCH trial data showing improved leg alignment with TransCon CNP in achondroplasia

-   Ascendis Pharma will present new follow-up data on its once-weekly TransCon CNP achondroplasia program at ICCBH 2026 in Montreal. \* Week 104 results from the pivotal ApproaCH trial are slated to show continued improvements in lower-limb alignment in treated children. \* A late-breaking poster will disclose 52-week findings from the Phase 2 COACH study, evaluating TransCon CNP combined with TransCon hGH. \* The company framed the data as supporting benefits across key disease complications, including limb growth, spinal canal narrowing, and extremity misalignment. \* TransCon CNP is marketed in the U.S. as Yuviwel following FDA clearance in February 2026; the monotherapy filing remains under EMA review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606251601PRIMZONEFULLFEED9752655) on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ASND.US](https://longbridge.com/en/quote/ASND.US.md)

## Related News & Research

- [Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong](https://longbridge.com/en/news/292392728.md)
- [Ascendis Pharma releases Week 104 ApproaCH trial radiographic data presentation on TransCon CNP in achondroplasia](https://longbridge.com/en/news/292126356.md)
- [Ascendis says TransCon CNP achondroplasia trial shows continued leg-alignment gains at Week 104](https://longbridge.com/en/news/291283724.md)
- [Corbus says Phase 1b CANYON-1 obesity trial of CRB-913 reaches last patient last visit](https://longbridge.com/en/news/294824963.md)
- [Is CenterPoint Energy (CNP) Undervalued After Its $700 Million Note Offering?](https://longbridge.com/en/news/294925805.md)